Skip to content

A randomized, open-label, controlled trial for Gu-Shen Ding-Chuan-Wan in the treatment of patients with novel coronavirus pneumonia (COVID-19) at recovery phase with Fei-Pi-Qi-Xu Zhen

Gu-Shen Ding-Chuan-Wan used in the recovery phase of 2019-nCoV pneumonia(FeiPiQiXuZheng): a randomized, open-label, controlled clinical trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030937
Enrollment
Unknown
Registered
2020-03-18
Start date
2020-03-19
Completion date
Unknown
Last updated
2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

The First Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Aged >=18 years; (2) 2019-nCoV pneumonia is diagnosed according to the standard of diagnosis and treatment; (3) Patient's condition has reached the standard of desolation / discharge specified according to the diagnosis and treatment plan; (4) According to the diagnosis standard, the syndrome differentiation of TCM is FeiPiQiXuZheng; (5) Volunteer to participate in the study and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Known or suspected allergy to the components of the study drug; (2) Acute infection of other viruses and bacteria has not been cured; (3) The function of liver and kidney was abnormal (ALT/AST>=2 times of the upper limit of normal value, SCr>1.5 times of the upper limit of normal value); (4) Participating in clinical trials of other drugs; (5) Pregnant and lactating women; or can not take effective contraceptive measures during the trial; (6) According to the judgment of the researcher, there are other situations that are not suitable for the experiment.

Design outcomes

Primary

MeasureTime frame
The change of TCM syndrome integral of deficiency of Fei-Pi-Qi-Xu Zhen;The results and changes of fatigue assessment scale at each time point;

Countries

China

Contacts

Public ContactLi Shi-yue

the First Affiliated Hospital of Guangzhou Medical University

lishiyue@188.com+86 13902233925

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026